Kiran Naqvi Selected Research

Primary Myelofibrosis (Myelosclerosis)

11/2021	The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis.
1/2017	Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.
8/2011	A potential role of ruxolitinib in leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kiran Naqvi Research Topics

Disease

20	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2023 - 12/2016
11	Neoplasms (Cancer) 02/2023 - 08/2011
10	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 02/2023 - 01/2018
9	Leukemia 01/2023 - 08/2011
9	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2021 - 01/2018
4	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2021 - 01/2019
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2023 - 01/2018
3	Primary Myelofibrosis (Myelosclerosis) 11/2021 - 08/2011
2	Thrombocytopenia (Thrombopenia) 11/2021 - 01/2021
2	Acute Promyelocytic Leukemia 01/2020 - 01/2019
2	Pleural Effusion (Pleural Effusions) 01/2020 - 01/2018
1	Pain (Aches) 07/2022
1	Confusion (Bewilderment) 01/2022
1	Inflammation (Inflammations) 01/2022
1	Emergence Delirium 01/2022
1	Delirium 01/2022
1	BCR-ABL Negative Atypical Chronic Myeloid Leukemia (Leukemia, Myeloid, Philadelphia Negative) 01/2021
1	Fatigue 01/2021
1	Exanthema (Rash) 01/2021
1	Neutropenia 01/2021
1	Philadelphia Chromosome 01/2020
1	Myeloid Leukemia (Leukemia, Myelocytic) 01/2020
1	Disease Resistance 01/2019
1	Myeloid Sarcoma (Chloroma) 01/2018
1	Multiple Myeloma 01/2018
1	Splenomegaly 01/2017
1	Hematologic Neoplasms (Hematological Malignancy) 08/2011

Drug/Important Bio-Agent (IBA)

9	venetoclaxIBA 01/2023 - 01/2020
4	ruxolitinibIBA 11/2021 - 08/2011
3	Azacitidine (5 Azacytidine)FDA Link 02/2023 - 11/2021
3	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2019
3	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2023 - 01/2018
3	Tyrosine Kinase InhibitorsIBA 11/2021 - 12/2019
3	Dasatinib (BMS 354825)FDA Link 01/2020 - 01/2018
3	Phosphotransferases (Kinase)IBA 01/2019 - 08/2011
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2022 - 11/2021
2	Lenalidomide (CC 5013)FDA Link 01/2021 - 01/2018
2	Decitabine FDA Link 01/2021 - 01/2020
2	bcr-abl Fusion ProteinsIBA 01/2020 - 01/2020
2	Arsenic Trioxide (Trisenox)FDA Link 01/2020 - 01/2019
2	Sorafenib (BAY 43-9006)FDA Link 11/2019 - 01/2019
1	pegaspargase (Oncaspar)FDA Link 11/2023
1	Glutamine (L-Glutamine)FDA Link 02/2023
1	GlutaminaseIBA 02/2023
1	milademetanIBA 01/2023
1	gilteritinibIBA 12/2022
1	Asu(1,6)- argipressin (VAS-A)IBA 07/2022
1	Interleukin-10 (Interleukin 10)IBA 01/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022
1	Calcium-Binding ProteinsIBA 01/2022
1	C-Reactive ProteinIBA 01/2022
1	Interleukin-8 (Interleukin 8)IBA 01/2022
1	InterleukinsIBA 01/2022
1	Insulin-Like PeptidesIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Programmed Cell Death 1 ReceptorIBA 11/2021
1	eltrombopag FDA Link 11/2021
1	pembrolizumabIBA 11/2021
1	LigandsIBA 11/2021
1	Interferon Type IIBA 01/2021
1	Drug CombinationsIBA 01/2021
1	isavuconazoleIBA 01/2021
1	CPX-351IBA 11/2020
1	RetinoidsIBA 01/2020
1	RNA Helicases (RNA Helicase)IBA 01/2020
1	AcidsIBA 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	Imatinib Mesylate (Gleevec)FDA Link 01/2020
1	CR 6IBA 01/2020
1	IMP DehydrogenaseIBA 01/2020
1	midostaurinIBA 11/2019
1	HomoharringtonineIBA 01/2019
1	binimetinibIBA 01/2019
1	fms-Like Tyrosine Kinase 3IBA 01/2019
1	MethyltransferasesIBA 01/2019
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2019
1	MitogensIBA 01/2019
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2019
1	DioxygenasesIBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	Janus Kinase 2IBA 01/2019
1	LY2510924IBA 01/2018
1	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 01/2018
1	fludarabineIBA 01/2018
1	Core Binding Factor Alpha 2 SubunitIBA 07/2017

Therapy/Procedure

14	Therapeutics 01/2023 - 01/2017
9	Drug Therapy (Chemotherapy) 01/2023 - 01/2019
3	Drug Tapering 11/2021 - 01/2018
2	Induction Chemotherapy 11/2019 - 12/2016
1	Critical Care (Surgical Intensive Care) 07/2022
1	Esophagectomy 01/2022
1	Remission Induction 01/2021
1	Immunotherapy 01/2020